Medical device acquisitions have picked up in 2024, with a handful of large purchases in the spotlight.
Johnson & Johnson’s $13.1 billion purchase of Shockwave Medical, which closed in May, remains the largest of the year so far. Boston Scientific has also been a prolific acquirer, closing its $3.7 billion purchase of Axonics in November and its $1.26 billion buy of Silk Road Medical in September following extended regulatory reviews.
While these big buys have made headlines, a theme for most companies in 2024 has been smaller bets targeting specific growth areas.
Last month, Boston reached agreements to buy Cortex, which makes diagnostic mapping technology for atrial fibrillation, and Intera Oncology, which makes a liver cancer treatment device, for undisclosed amounts.
Stryker, in September, bought Nico, a company that makes devices for navigating through the brain and removing clots and tumors, also for an unnamed price.
Artificial intelligence has been a focus this year, reflected in purchases by GE Healthcare and Samsung Medison. In November, Tempus AI, which provides precision medicine solutions, agreed to pay $600 million for Ambry Genetics, which offers hereditary cancer screening.
Here’s a collection of MedTech Dive’s coverage of dealmaking so far in 2024. The roundup will be updated as more deals are announced:
